T J Samson Community Hospital Home Care Hospice 1301 North Race Street, Glasgow, KY, 42142 | |
(270) 651-4430 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
The concept is based on the interaction of resonant semiconductor iron oxide Fe2O3 nanoparticles with light. Particles previously loaded with the antitumor drug are injected in vivo and further accumulate at the tumor areas.
Dr. Bernard Th-baud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.
› Verified 1 days ago
Name | T J Samson Community Hospital Home Care Hospice |
---|---|
Location | 1301 North Race Street, Glasgow, Kentucky |
Hospice ID | 181531 |
Category | Part of a hospital |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
SSA county code | 040 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
The concept is based on the interaction of resonant semiconductor iron oxide Fe2O3 nanoparticles with light. Particles previously loaded with the antitumor drug are injected in vivo and further accumulate at the tumor areas.
Dr. Bernard Th-baud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.
› Verified 1 days ago
NPI Number | 1376574806 |
Organization Name | T J Samson Community Hospital |
Address | 1301 N Race St Glasgow, Kentucky, 42141 |
Phone Number | (270)651-4430 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
The concept is based on the interaction of resonant semiconductor iron oxide Fe2O3 nanoparticles with light. Particles previously loaded with the antitumor drug are injected in vivo and further accumulate at the tumor areas.
Dr. Bernard Th-baud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.
› Verified 1 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 26.6 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
Patients who got timely treatment for shortness of breath | 100.0 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
The concept is based on the interaction of resonant semiconductor iron oxide Fe2O3 nanoparticles with light. Particles previously loaded with the antitumor drug are injected in vivo and further accumulate at the tumor areas.
Dr. Bernard Th-baud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.
› Verified 1 days ago
Home Health Aides | 2 |
Counselors | 1 |
Homemakers | 1 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 6 |
Other Personnel | 10 |
Total Employees | 22 |
---|
News Archive
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
The concept is based on the interaction of resonant semiconductor iron oxide Fe2O3 nanoparticles with light. Particles previously loaded with the antitumor drug are injected in vivo and further accumulate at the tumor areas.
Dr. Bernard Th-baud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.
› Verified 1 days ago
Homemakers | 1 |
Others | 5 |
Total Volunteers | 6 |
---|
News Archive
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
The concept is based on the interaction of resonant semiconductor iron oxide Fe2O3 nanoparticles with light. Particles previously loaded with the antitumor drug are injected in vivo and further accumulate at the tumor areas.
Dr. Bernard Th-baud lives in two very different worlds. As a specialist in the Stollery Children's Hospital's Neonatal Intensive Care Unit at the Royal Alexandra Hospital, he cares for tiny babies, many of whom struggle for breath after being born weeks before they are due.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.
› Verified 1 days ago
T J Samson Community Hospital Home Care Hospice Location: 1301 North Race Street, Glasgow, Kentucky, 42142 Phone: (270) 651-4430 |